| October 9, 2014 | ISSUE NUMBER 372 VOL 4 |
|
Healthcare Reform
The “Value” of Rx’s under Obamacare
In the wake of the recent declaration by new HHS Secretary, Sylvia Burwell, that “Obamacare is working”, it’s time for American Rx product managers and marketers to step back and consider where we have travelled since January 1st of this year. Tom Norton provides a few key remembrances ...Read more
Healthcare Reform
Five Measures to Cope with the “Side Effects” of Healthcare Reform
The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans. But along with such safeguards and the broad extension of coverage come some significant challenges or “side effects.” Sydney Rubin lists five ways to deal with the challenges ...Read more
ZS AffinityMonitorTM finds 29% of inaccessible physicians interact with non-personal promotion.
 Read the report
to learn how pharmacos can determine the right combination of high impact and low cost channels for each prescriber.
Healthcare
How a New Demographic is Shaping US Healthcare
For the first time in decades, the 18-to-34 year-old set now claims the largest share (23.5%) of the US population. And these so-called millennials carry the numerical clout to color everything from the nation’s cultural landscape to the conduct of basic business practices like marketing, reputation and customer engagement. William Looney reports
...Read more
Covance MarketPlace. Connect Right from the Start.
Find the right partner with the desire and resources to help you realize your molecule’s potential. Through our private, secure and exclusive online portal, you can share information about your molecule to potential investors or partners. It's one more innovative way to transform the profile and success of your program, delivered by the only global drug development partner with expertise spanning preclinical, clinical and commercial phases.  Learn more
Big Data
Pharm Exec Global: Big Data Special
In the latest issue of the Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; Successfully integrating Big Data analytics with a company’s existing systems; In-silico modeling and real-word outcomes; and more
...Read more
Global
European Pharma Innovation: A Critical Perspective
Economist Fabio Pammolli has been selected by the European Commission as the first author of a set of critical overviews on the state of the industry from a national, regional and global perspective. Pharm Exec recently sat down with Pammolli to hear his views on drug innovation within the European industry—and how government is measuring up to his recommendations for a dramatic change in industrial strategy to accommodate a far more competitive marketplace
...Read more
|
|
|
|
 //With 13.4 million francs ($14 million) total compensation last year, Severin Schwan, CEO of Roche, is still the best-paid Swiss executive, closely followed by Joseph Jimenez, CEO at rival Novartis, according to a study by corporate governance group Ethos.//Sucampo Pharmaceuticals (Bethesda, MD) announced that Cary J. Claiborne, Chief Financial Officer, is leaving the company to pursue other interests. Mr. Claiborne will continue in his current role through November 7, 2014, and Sucampo has initiated a search for a new CFO.//Fibrocell Science (Exton, PA) appointed Kimberly M. Smith, the company's controller, to serve as Interim Chief Financial Officer.//Cerulean Pharma (Cambridge, MA) added Susan L. Kelley, M.D., to its Board of Directors.// |
|
|
|
|
|
 |
|
 |
|
| |
 |
|
 |
 Which of these countries do you believe will drive most of pharma's growth over the next 12 months?
|
|
|
|
